{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+Globulin+Intravenous+%28Human%29&page=20",
    "query": {
      "intervention": "Immune Globulin Intravenous (Human)",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 461,
    "total_pages": 47,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+Globulin+Intravenous+%28Human%29&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+Globulin+Intravenous+%28Human%29&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T11:11:13.802Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06594068",
      "title": "Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Anifrolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 130 Years · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2026-01-16",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-16T11:11:13.802Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06594068"
    },
    {
      "nct_id": "NCT04776629",
      "title": "A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis",
        "Inflammation",
        "Coronary Artery Disease",
        "Cardiometabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "Orticumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abcentra",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2021-06-30",
      "completion_date": "2022-11-11",
      "has_results": true,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-10-16T11:11:13.802Z",
      "location_count": 13,
      "location_summary": "Scottsdale, Arizona • Santa Monica, California • Tustin, California + 9 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Vista",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04776629"
    },
    {
      "nct_id": "NCT06659029",
      "title": "Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Anifrolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 442,
      "start_date": "2025-07-01",
      "completion_date": "2031-04-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-16T11:11:13.802Z",
      "location_count": 1,
      "location_summary": "Wilmington, North Carolina",
      "locations": [
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06659029"
    },
    {
      "nct_id": "NCT06400472",
      "title": "A Study of Sofe-M in Participants With Selected Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Neoplasms",
        "Endometrial Neoplasms",
        "Uterine Cervical Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Triple Negative Breast Neoplasms",
        "Pancreatic Neoplasm",
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Sofe-M",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 575,
      "start_date": "2024-05-20",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-10-16T11:11:13.802Z",
      "location_count": 11,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Atlanta, Georgia + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Mineola",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06400472"
    },
    {
      "nct_id": "NCT04661839",
      "title": "A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "COVID-HIGIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (saline)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 28,
      "start_date": "2020-12-24",
      "completion_date": "2021-07-27",
      "has_results": true,
      "last_update_posted_date": "2025-06-08",
      "last_synced_at": "2026-10-16T11:11:13.802Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04661839"
    },
    {
      "nct_id": "NCT07399951",
      "title": "Washington University WU 409: Immune Responses to Rabies Vaccine.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Imovax",
          "type": "DRUG"
        },
        {
          "name": "RabAvert",
          "type": "DRUG"
        },
        {
          "name": "HyperRAB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2023-10-19",
      "completion_date": "2025-10-01",
      "has_results": true,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-16T11:11:13.802Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07399951"
    },
    {
      "nct_id": "NCT02269163",
      "title": "Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Intravenous",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prometic's Immune Globulin Intravenous 10%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Prometic Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "2 Years to 80 Years"
      },
      "enrollment_count": 82,
      "start_date": "2016-01-26",
      "completion_date": "2019-01-11",
      "has_results": true,
      "last_update_posted_date": "2021-11-05",
      "last_synced_at": "2026-10-16T11:11:13.802Z",
      "location_count": 13,
      "location_summary": "Irvine, California • Los Angeles, California • Centennial, Colorado + 10 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02269163"
    },
    {
      "nct_id": "NCT01178216",
      "title": "Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Rituxan",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Stanley Jordan, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 41,
      "start_date": "2013-09",
      "completion_date": "2017-07-28",
      "has_results": true,
      "last_update_posted_date": "2018-10-26",
      "last_synced_at": "2026-10-16T11:11:13.802Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01178216"
    },
    {
      "nct_id": "NCT04879368",
      "title": "RegoNivo vs Standard of Care Chemotherapy in AGOC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastro-Oesophageal Cancer"
      ],
      "interventions": [
        {
          "name": "Regorafenib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Trifluridine/Tipracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Australasian Gastro-Intestinal Trials Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 462,
      "start_date": "2021-05-05",
      "completion_date": "2025-04-30",
      "has_results": true,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-10-16T11:11:13.802Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Sioux City, Iowa + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        },
        {
          "city": "Edgewood",
          "state": "Kentucky"
        },
        {
          "city": "Rapid City",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04879368"
    },
    {
      "nct_id": "NCT05180474",
      "title": "GEN1047 for Solid Tumors - First in Human (FIH) Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer, Breast Neoplasms",
        "Endometrial Cancer, Endometrial Neoplasm",
        "Ovarian Cancer, Ovarian Neoplasms",
        "Squamous Non Small Cell Lung Cancer (NSCLC-SCC)"
      ],
      "interventions": [
        {
          "name": "GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 179,
      "start_date": "2021-12-13",
      "completion_date": "2026-03-25",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-10-16T11:11:13.802Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05180474"
    }
  ]
}